Issues raised in clinical researches using anti-vascular endothelial growth factor drugs to treat choroidal neovascularization
- Author:
- No author available
- Journal Title:
- Chinese Journal of Ocular Fundus Diseases
- Issue:
- 6
- DOI:
- 10.3760/cma.j.issn.1005-1015.2011.06.001
- Key Word:
- 脉络膜新生血管化/治疗;血管内皮生长因子类;述评;Choroidal neovascularization/therapy;Vascular endothelial growth factors;Editorial
Abstract： Anti-vascular endothelial growth factor (VEGF) drugs have become the first-line medications for the treatment of choroidal neovascularization (CNV).Its efficacy and safety have been confirmed by evidence-based medicine and a large number of clinical studies.However there are several issues need to be discussed before reaching a consensus for the clinical application of anti-VEGF drugs.These issues include,but not limited to the individual treatment regimen for different CNV lesions,the best anti-VEGF drug regimen,the indications and schemes of combination therapy,the factors affecting the efficacy,the potential risks of systemic and local deliveries.How to establish a reasonable personalized regimen of anti-VEGF drugs is the 1st issue need to be explored.Ranibizumab will come into China market soon.We need utilize the existing evidence-based medical research findings; take our advantages of rich resources of patients to investigate those issues to further promote the anti-VEGF applications in China.
- [1]戴虹,杨絮,喻晓兵,等.抗血管内皮生长因子单克隆抗体Ranibizumab治疗渗出型老年性黄斑变性临床观察[J].2008,(3).
- [2]戴虹,岳枚,杨絮,等.抗血管内皮生长因子单克隆抗体Ranibizumab联合光动力疗法治疗渗出型年龄相关性黄斑变性的临床观察[J].2011,(2).
- [3]戴虹,喻晓兵,龙力,等.抗血管内皮生长因子单克隆抗体ranibizumab治疗渗出型老年性黄斑变性方案的探讨[J].2010,(1).
- [4]Pauleikhoff D,Kirchhof B.Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity".[J].2011,249(5).
- [5]Souied EH,Lalloum F,Bastuji Garin.Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.[J].2010,30(3).
- [6]Grunwald JE,Fine SL,Maguire MG,etc.Ranibizumab and bevacizumab for neovascular age-related macular degeneration.[J].2011,364(20).
- [7]Ringens PJ,Schouten JS,van der Reis MI,etc.A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.[J].2011,31(8).
- [8]Ito R,Arakawa A,Inoue M,etc.Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.[J].2010,30(5).
- [9]Mitchell P,Korobelnik JF,Lanzetta.Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.[J].2010,94(1).
- [10]Cousins SW,Schulman KA,Hammill BG,etc.Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.[J].2010,128(10).
- [11]Boyer DS,Awh CC,Antoszyk AN,etc.Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.[J].2007,114(2).
- [12]Brown DM,Chung CY,Kim RY,etc.Ranibizumab for neovascular age-related macular degeneration.[J].2006,355(14).
- [13]Rosenfeld PJ,Shapiro H,Tuomi L,etc.Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.[J].2011,118(3).
- [14]Neil M. Bressler,Tom S. Chang,Ivan J. Suñer,etc.Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical Trial Results from MARINA and ANCHOR[J].2010,117(4).